Core Viewpoint - Danaher has experienced a decline in stock performance recently, with a -3.4% return over the past month, contrasting with the S&P 500's +1.6% change, raising questions about its future stock trajectory [1] Earnings Estimates Revisions - The current quarter's earnings estimate for Danaher is projected at $1.72 per share, reflecting a -27.1% change year-over-year, with the consensus estimate remaining unchanged over the last 30 days [3] - For the current fiscal year, the consensus earnings estimate is $7.62, indicating a +0.5% change from the previous year, also unchanged over the last month [3] - The next fiscal year's consensus earnings estimate is $8.70, suggesting a +14.1% change from the prior year, with no changes in the estimate over the past month [3] Revenue Growth Forecast - Danaher's consensus sales estimate for the current quarter is $5.64 billion, indicating a -21.3% year-over-year change [5] - The sales estimates for the current and next fiscal years are $24.09 billion and $26.1 billion, reflecting changes of -12.7% and +8.3%, respectively [5] Last Reported Results and Surprise History - In the last reported quarter, Danaher generated revenues of $6.41 billion, a -23.5% year-over-year decline, with an EPS of $2.09 compared to $2.87 a year ago [6] - The reported revenues exceeded the Zacks Consensus Estimate of $5.99 billion by +6.93%, and the EPS surprise was +10% [6] - Danaher has consistently beaten consensus EPS and revenue estimates in the trailing four quarters [7] Valuation - Danaher's valuation metrics, including price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), are essential for assessing whether the stock is fairly valued [8] - The Zacks Value Style Score indicates that Danaher is graded F, suggesting it is trading at a premium compared to its peers [9] Conclusion - The analysis indicates that despite recent challenges, Danaher's Zacks Rank 2 suggests potential for outperforming the broader market in the near term [10]

The latest trading session saw Danaher (DHR) ending at $245.94, denoting a -0.75% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0.72%. At the same time, the Dow lost 1%, and the tech-heavy Nasdaq lost 0.95%.The industrial and medical device maker's shares have seen a decrease of 3.28% over the last month, not keeping up with the Conglomerates sector's gain of 2.78% and the S&P 500's gain of 2.16%.The upcoming earnings release of Danaher will be of grea ...

WASHINGTON, March 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading ...

Danaher (DHR) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this industrial and medical device maker have returned +0.4% over the past month versus the Zacks S&P 500 composite's +3.6% change. The Zacks Diversified Operations industry, to which Danaher belongs, has gained 6.5% over this period. Now the key question is: Where could the stock be headed in ...

Danaher (DHR) closed the most recent trading day at $251.47, moving +0.83% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.63% for the day. Meanwhile, the Dow experienced a rise of 0.2%, and the technology-dominated Nasdaq saw an increase of 0.82%.The industrial and medical device maker's shares have seen a decrease of 0.24% over the last month, not keeping up with the Conglomerates sector's gain of 5.08% and the S&P 500's gain of 1.76%.Analysts and investors ...

Group 1: Company Performance - Danaher Corporation (DHR) is experiencing growth in its Life Sciences segment, driven by stable demand in academic and life science research markets, particularly for plasmids, proteins, and gene editing solutions [1] - The company has seen positive market responses to new products like IDBS' Polar Insight and Molecular Devices' CellXpress.ai, which enhance drug discovery processes [1] - In the Diagnostics unit, new solutions such as Beckman Coulter's DxI 9000 immunoassay analyzer are gaining traction [1] Group 2: Acquisitions and Financials - Danaher acquired Abcam plc for $5.7 billion in December 2023, which is expected to enhance its Life Sciences segment and address significant healthcare challenges [2] - The acquisition contributed to a 0.5% increase in total revenues for Danaher in 2023 [2] - The company paid dividends of $821 million in 2023, a 0.4% increase year-over-year, and raised its dividend by 12.5% to 27 cents per share in February 2024 [2] Group 3: Segment Challenges - The Biotechnology and Diagnostics segments are facing challenges, with revenues declining by 11.5% and 18% year-over-year, respectively, due to reduced demand for COVID-related products [4] - High debt levels are a concern, with Danaher reporting long-term debt of $16.7 billion and current liabilities of $8.3 billion, exceeding cash equivalents of $5.9 billion [4] Group 4: Market Comparison - Over the past three months, Danaher has gained 10.4%, outperforming the industry growth of 5.9% [4]

Company Performance - Danaher (DHR) closed at $252.80, reflecting a -0.35% change from the previous day, underperforming the S&P 500's 0.11% loss [1] - Over the past month, Danaher's shares appreciated by 4.42%, underperforming the Conglomerates sector's gain of 7.86% but outperforming the S&P 500's gain of 2.7% [1] - Upcoming earnings per share (EPS) are projected to be $1.74, indicating a 26.27% decrease from the same quarter last year, with revenue forecasted at $5.64 billion, a 21.31% decline compared to the prior year [1] Annual Estimates - Zacks Consensus Estimates for the annual period anticipate earnings of $7.63 per share and revenue of $24.09 billion, reflecting shifts of +0.66% and -12.73% from the last year [2] - Recent adjustments to analyst estimates for Danaher indicate changing near-term business trends, with positive revisions suggesting analysts' confidence in the company's performance [2] Valuation Metrics - Danaher has a Forward P/E ratio of 33.25, which is a premium compared to the industry's average Forward P/E of 17.86 [3] - The company currently has a PEG ratio of 3.85, compared to the industry's average PEG ratio of 2.25 [3] - The Diversified Operations industry, part of the Conglomerates sector, holds a Zacks Industry Rank of 51, placing it within the top 21% of over 250 industries [3]

Danaher Corporation (NYSE:DHR) TD Cowen 44th Annual Health Care Conference March 5, 2024 11:10 AM ET Company Participants Rainer Blair - President, CEO Conference Call Participants Dan Brennan - TD Cowen Dan Brennan Thank you. Dan Brennan from TD Cowen Life Science Tools Diagnostics. And we're here at 44th Annual Global Healthcare Conference. Really pleased to be joined here on the stage Rainer Blair, President and CEO of Danaher Corporation. So Rainer, thank you very much for being here. Rainer Blair Thank ...

Danaher (DHR) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this industrial and medical device maker have returned +3.3% over the past month versus the Zacks S&P 500 composite's +5.2% change. The Zacks Diversified Operations industry, to which Danaher belongs, has gained 6.7% over this period. Now the key question is: Where could the stock be headed in the near term?Althoug ...

A month has gone by since the last earnings report for Danaher (DHR) . Shares have added about 6.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Danaher due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Danaher Q4 Earnings Beat, Biotechnology Sales Dip Y/YDanaher’s ...